epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2016-15-2-77-84epidemiology-153Research ArticleИНФОРМАЦИЯ ЕРБ ВОЗWHO/EUROPE INFORMATIONОсобенности изотипической структуры вирусспецифического системного гуморального иммунного ответа у взрослых волонтеров, привитых инактивированными субъединичными моновакцинами против гриппа А(H1N1)pdm09Features of Isotypic Structure of Virus-Specific Systemic Humoral Immune Response in Adult Volunteers Immunized with Inactivated Monovalent Subunit Vaccines against Pandemic Influenza A(H1N1)pdm09ВасильеваА. А.VasilevaA. A.noemail@neicon.ruКривицкаяВ. З.KrivitskayaV. Z.noemail@neicon.ruВойцеховскаяЕ. М.VojcekhovskayaE. M.noemail@neicon.ruВакинВ. С.VakinV. S.noemail@neicon.ruКузнецоваЕ. В.KuznecovaE. V.noemail@neicon.ruПетроваЕ. Р.PetrovaE. R.noemail@neicon.ruГоА. А.GoA. A.noemail@neicon.ruЛьвовН. И.LvovN. I.noemail@neicon.ruСомининаА. А.SomininaA. A.noemail@neicon.ruФГБУ «НИИ гриппа» Минздрава РоссииРоссияThe Federal State Budgetary Institution «Research Influenza Institute» of Ministry of Healthcare of the Russian FederationRussian FederationФГБУ ВОУ ВПО «Военно-медицинская академия им. С.М. Кирова» Минобороны РоссииРоссияFederal State Military Educational Institution of Additional Professional Education «Military Medical Academy named S.M. Kirov» Ministry of Defense of the Russian FederationRussian Federation2016200420161527784Copyright © Васильева А.А., Кривицкая В.З., Войцеховская Е.М., Вакин В.С., Кузнецова Е.В., Петрова Е.Р., Го А.А., Львов Н.И., Соминина А.А., 20162016Васильева А.А., Кривицкая В.З., Войцеховская Е.М., Вакин В.С., Кузнецова Е.В., Петрова Е.Р., Го А.А., Львов Н.И., Соминина А.А.Vasileva A.A., Krivitskaya V.Z., Vojcekhovskaya E.M., Vakin V.S., Kuznecova E.V., Petrova E.R., Go A.A., Lvov N.I., Sominina A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/153

Проведен сравнительный анализ изотипической структуры системного гуморального иммунного ответа на вирус гриппа A(H1N1) pdm09 у взрослых волонтеров, привитых двумя отечественными инактивированными субъединичными моновакцинами против пандемического гриппа. Группу сравнения составили пациенты, перенесшие грипп A(H1N1)pdm09. По сравнению с пациентами, переболевшими пандемическим гриппом, в группе волонтеров, привитых инактивированными моновакцинами, наблюдали более активный ответ на вирус гриппа A(H1N1)pdm09 со стороны антител как с вируснейтрализующим потенциалом (IgG1, IgG2, IgG3), так и ассоциированных с аллергическим воспалением (IgG и IgE). Показана высокая активность вирусспецифичных сывороточных IgA как у переболевших пациентов, так и у вакцинированных волонтеров. По данным РТГА, гемагглютинирующая противовирусная активность антител в поствакцинальных сыворотках привитых волонтеров в отличие от сывороток, полученных от инфицированных пациентов в фазе реконвалесценции, превышала защитный уровень (1:40).

An isotypic structure of system antibody response to influenza A(H1N1)pdm09 was analyzed in adult volunteers vaccinated with two inactivated monovalent subunit vaccines against pandemic influenza. The comparison group consisted of patients infected with influenza A(H1N1)pdm09 virus. In vaccinated volunteers the more active response of influenza-specific antibodies both with neutralizing properties (IgG1, IgG2, IgG3) and associated with allergic inflammation (IgG and IgE) was observed in comparison with infected patients. The high activity of the virus-specific serum IgA was observed both in infected patients and vaccinated volunteers. Antiviral hemagglutinating activity of antibodies in post-vaccination sera of vaccinated volunteers, unlike sera obtained from infected patients in the phase of recovery, were higher than protective level (1:40) according to HAI data.

инактивированные гриппозные вакциныпандемический грипп A(H1N1)pdm09гуморальный иммунитетизотипы иммуноглобулиноввзрослые волонтерыпереболевшие гриппом пациентыinactivated influenza vaccinespandemic influenza A(H1N1)pdm09humoral immunityimmunoglobulin isotypesadult volunteersrecover from influenza patientsReferencesChiu C., Ellebedy A.H., Wrammert J., Ahmed R. B cell responses to influenza infection and vaccination. Curr. Top. Microbiol. Immunol. 2015; 386: 381-398.Chiu C., Ellebedy A.H., Wrammert J., Ahmed R. B cell responses to influenza infection and vaccination. Curr. Top. Microbiol. Immunol. 2015; 386: 381–398.Gomez Lorenzo M.M., Fenton M. J. Immunobiology of influenza vaccines. Chest. 2013; 143 (2): 502 - 510.Gomez Lorenzo M.M., Fenton M.J. Immunobiology of influenza vaccines. Chest. 2013; 143 (2): 502 – 510.Chung E.H. Vaccine allergies. Clin. Exp. Vaccine. Res. 2014; 3 (1): 50 - 57.Chung E.H. Vaccine allergies. Clin. Exp. Vaccine. Res. 2014; 3 (1): 50 – 57.Lv J., Wang D., Hua Y.H., Pei S.J., Wang J., Hu W.W. et al. Pulmonary immune responses to 2009 pandemic influenza A (H1N1) virus in mice. BMC Infect Dis. 2014; 14: 197.Lv J., Wang D., Hua Y.H., Pei S.J., Wang J., Hu W.W. Wang X.L., Jia N., Jiang Q.S. Pulmonary immune responses to 2009 pandemic influenza A (H1N1) virus in mice. BMC Infect Dis. 2014; 14:197.Ельшина Г.А., Лонская Н.И., Мефед К.М., Пучкова Н.Г., Чирун Н.В., Горбунов М.А. и др. Результаты клинических исследований пандемических субъединичных гриппозных моновакцин. Биопрепараты. 2010; 4 (40): 31 - 36.Elshina G.A., Lonskaya N.I., Mefed K.M., Puchkova N.G., Chirun N.V., Gorbunov M.А. et al. Results of clinical research of pandemic monovalent influenza vaccine. Вiopreparaty. 2010; 4 (40): 31 – 36 (in Russian).Ельшина Г.А., Харит С.М., Романенко В.В., Комлева С.В., Пучкова Н.Г., Чирун Н.В. и др. Результаты изучения безопасности и иммуногенности отечественных субъединичных адъювантных пандемических моновакцин группы Гриппол® у детей от 6 месяцев до 17 лет. Эпидемиология и Вакцинопрофилактика. 2011; 2 (57): 41 - 46.Elshina G.A., Harith S.M., Romanenko V.V., Komleva S.V., Puchkova N.G., Chyrun N.V. et al. The results of the study of the safety and immunogenicity of adjuvanted subunit of domestic pandemic monovalent group Grippol® in children from 6 months to 17 years. Еpidemiology & Vacinal Prevention. 2011; 2 (57): 41 – 46 (in Russian).Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976; 1 (72): 248 - 254.Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal. Biochem. 1976; 1 (72): 248 – 254.Соминина А.А., Кривицкая В.З., Войцеховская Е.М., Медведева Н.А., Липина Н.В., Потапенко Л.Б. Практические рекомендации по диагностике вирусных инфекций. Санкт-Петербург: 2005: 21.Sominina A.A., Krivitskaya V.Z., Voytsekhovskaya E.M., Medvedeva N.A., Lipina N.V., Potapenko L.B. Practical Guidelines for the diagnosis of viral infections. St. Petersburg: 2005; 21 (in Russian).Palladino G., Mozdzanowska K., Washko G., Gerhard W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J. Virol. 1995; 69(4): 2075 - 2081.Palladino G., Mozdzanowska K., Washko G., Gerhard W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J. Virol. 1995; 69 (4): 2075 – 2081.Pedersen G.K., H schler K., ie Solbak S.M., Bredholt G., Pathirana R.D., Afsar A. et al. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine. 2014; 32 (35): 4550 - 4557.Pedersen G.K., Höschler K., Øie Solbak S.M., Bredholt G., Pathirana R.D., Afsar A. et al. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine. 2014; 32 (35): 4550 – 4557.El-Madhun A.S., Cox R.J., Haaheim L.R. The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. J Infect Dis. 1999; 180 (4): 1356 - 1360.El-Madhun A.S., Cox R.J., Haaheim L.R. The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. J Infect Dis. 1999; 180 (4): 1356 – 1360.Frasca D., Diaz A., Romero M., Mendez N., Landin A.M., Blomberg B. Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011 -2012 influenza vaccine season. Immunity and Ageing. 2013; 10:14.Frasca D., Diaz A., Romero M., Mendez N., Landin A.M., Blomberg B. Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011 – 2012 influenza vaccine season. Immunity and Ageing. 2013; 10:14.Arankalle V.A., Lole K.S., Arya R.P., Tripathy A.S., Ramdasi A.Y., Chadha M.S. et al. Role of host immune response and viral load in the differential outcome of pandemic H1N1 (2009) influenza virus infection in Indian patients. PLoS One. 2010; 5(10): e13099.Arankalle V.A., Lole K.S., Arya R.P., Tripathy A.S., Ramdasi A.Y., Chadha M.S. et al. Role of host immune response and viral load in the differential outcome of pandemic H1N1 (2009) influenza virus infection in Indian patients. PLoS One. 2010; 5(10): e13099.Concept paper on the revision of the CPMP/BWP note for guidance on harmonization of requirements for influenza vaccines. London; 2001, CPMP/ EWP/1045/01.Concept paper on the revision of the CPMP/BWP note for guidance on harmonization of requirements for influenza vaccines. London; 2001, CPMP/EWP/1045/01.Vidarsson G., Dekkers G., Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 2014; 5: 520.Vidarsson G., Dekkers G., Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 2014; 5: 520.Reichert T., Chowell G., Nishiura H., Christensen R.A., McCullers J.A. Does Glycosylation as a modifier of Original Antigenic Sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza? BioMed. Central. Infect. Dis. 2010; 10: 5 - 9.Reichert T., Chowell G., Nishiura H., Christensen R.A., McCullers J.A. Does Glycosylation as a modifier of Original Antigenic Sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza? BioMed. Central. Infect. Dis. 2010; 10: 5 – 9.Gordon C.L., Johnson P.D., Permezel M., Holmes N.E., Gutteridge G., McDonald C.F. et al. Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency. Clin. Infect. Dis. 2010; 50 (5): 672 - 678.Gordon C.L., Johnson P.D., Permezel M., Holmes N.E., Gutteridge G., McDonald C.F. et al. Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency. Clin. Infect. Dis. 2010; 50 (5): 672 – 678.Yamamoto T., Mizoguchi Y., Kaneno H., Yamamoto K., Inoue Y., Kawashima H. et al. Serum immunoglobulin G subclass levels and estimated clinical severity caused by possible influenza A(H1N1)pdm2009 infection. J. Infect. Chemother. 2013; 19: 833 - 842.Yamamoto T., Mizoguchi Y., Kaneno H., Yamamoto K., Inoue Y., Kawashima H. et al. Serum immunoglobulin G subclass levels and estimated clinical severity caused by possible influenza A(H1N1)pdm2009 infection. J. Infect. Chemother. 2013; 19: 833 – 842.Burton O.T., Oettgen H.C. Beyond immediate hypersensitivity: evolving roles for IgE antibodies in immune homeostasis and allergic diseases. Immunol. Rev. 2011; 242 (1): 128 - 143.Burton O.T., Oettgen H.C. Beyond immediate hypersensitivity: evolving roles for IgE antibodies in immune homeostasis and allergic diseases. Immunol. Rev. 2011; 242(1): 128 – 143.Hofmaier S., Comberiati P., Matricardi P.M. Immunoglobulin G in IgE-mediated allergy and allergen-specific immunotherapy. Eur. Ann. Allergy. Clin. Immunol. 2014; 46 (1): 6 - 11.Hofmaier S., Comberiati P., Matricardi P.M. Immunoglobulin G in IgE-mediated allergy and allergen-specific immunotherapy. Eur. Ann. Allergy. Clin. Immunol. 2014; 46 (1): 6 – 11.Chung E.H. Vaccine allergies. Clin. Exp. Vaccine. Res. 2014; 3 (1): 50 - 57.Chung E.H. Vaccine allergies. Clin. Exp. Vaccine. Res. 2014; 3(1): 50-57.Smith-Norowitz T.A., Kusonruksa M., Wong D., Norowitz M.M., Joks R., Durkin H.G. et al. Long-term persistence of IgE anti-influenza A HIN1 virus antibodies in serum of children and adults following influenza A vaccination with subsequent H1N1 infection: a case study. J. Inflamm Res. 2012; 5: 111 - 116.Smith-Norowitz T.A., Kusonruksa M., Wong D., Norowitz M.M., Joks R., Durkin H.G. et al. Long-term persistence of IgE anti-influenza A HIN1 virus antibodies in serum of children and adults following influenza A vaccination with subsequent H1N1 infection: a case study. J. Inflamm Res. 2012; 5: 111 – 116.Julkunen I., Hovi T., Seppl I., M kel O. Immunoglobulin G subclass antibody responses in influenza A and parainfluenza type 1 virus infections. Clin. Exp. Immunol. 1985; 60 (1): 130 - 138.Julkunen I., Hovi T., Seppälä I., Mäkelä O. Immunoglobulin G subclass antibody responses in influenza A and parainfluenza type 1 virus infections. Clin. Exp. Immunol. 1985; 60 (1): 130 – 138.Monteiro R.C. Role of IgA and IgA fc receptors in inflammation. J. Clin. mmunol. 2010; 30 (1): 1 - 9.Monteiro R.C. Role of IgA and IgA fc receptors in inflammation. J. Clin. mmunol. 2010; 30 (1): 1 – 9.Li Z.N., Lin S.C., Carney P.J., Li J., Liu F., Lu X. et al. IgM, IgG, and IgA antibody responses to influenza A(H1N1)pdm09 hemagglutinin in infected persons during the first wave of the 2009 pandemic in the United States. Clin. Vaccine. Immunol. 2014; 21 (8): 1054 - 1060.Li Z.N., Lin S.C., Carney P.J., Li J., Liu F., Lu X. et al. IgM, IgG, and IgA antibody responses to influenza A(H1N1)pdm09 hemagglutinin in infected persons during the first wave of the 2009 pandemic in the United States. Clin. Vaccine. Immunol. 2014; 21 (8): 1054 – 1060.

The authors declare that there are no conflicts of interest present.